Glasgow Dental School and Hospital, Faculty of Medicine, University of Glasgow, UK.
Curr Opin Infect Dis. 2010 Dec;23(6):560-6. doi: 10.1097/QCO.0b013e32833e5850.
A multidisciplinary approach to the treatment and management of biofilms has resulted from the growing appreciation of the role that biofilms play in modern medicine. Conventional antimicrobial agents are generally ineffective against biofilms, and as a result novel laboratory-based and clinical strategies have emerged. The purpose of this review is to analyse the recent literature relating to novel treatment strategies targeting the growing spectrum of clinically relevant biofilms.
Microscopy and molecular techniques have provided greater insights into identifying the key bacterial and fungal biofilm pathogens. Knowledge of these microorganisms has provided a foundation for the development of specific molecules, often microbial derived, with antimicrobial and/or biofilm disruptive properties, augmenting conventional antibiotics treatments. The validity of some such rationally designed therapeutics has been explored in clinical trials.
Biofilms are inherently difficult to treat, and mechanical disruption is the mainstay of clinical management. With scientific progress in molecular microbiology, there is an abundance of newly discovered molecules and pathways, providing novel therapeutic and prophylactic targets.
由于人们越来越认识到生物膜在现代医学中的作用，多学科方法已被用于生物膜的治疗和管理。传统的抗菌药物通常对生物膜无效，因此出现了新的基于实验室和临床的策略。本综述的目的是分析最近与针对不断增加的临床相关生物膜的新型治疗策略相关的文献。
显微镜和分子技术为鉴定关键的细菌和真菌生物膜病原体提供了更深入的了解。对这些微生物的了解为开发具有抗菌和/或生物膜破坏特性的特定分子提供了基础，这些分子通常来源于微生物，可增强常规抗生素治疗。一些经过合理设计的治疗方法的有效性已在临床试验中得到探索。
生物膜的治疗难度很大，机械破坏是临床管理的主要方法。随着分子微生物学的科学进步，有大量新发现的分子和途径，为新的治疗和预防靶点提供了依据。
